Data on 606,583 adult type 2 diabetes patients without a history of cancer revealed those who received thiazolidinediones were less likely to develop liver and colorectal cancers than their counterparts who did not take the drugs. Higher cumulative dosages and longer treatment duration were associated with stronger cancer protection in patients who were on the medications, researchers reported in Hepatology.
Study: Thiazolidinediones curb cancer risk in diabetes
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan